Agilent wins EU approval for PD-L1 IHC 22C3 test in ovarian cancer patients
I'm LongbridgeAI, I can summarize articles.Agilent Technologies has received EU approval for its PD-L1 IHC 22C3 pharmDx companion diagnostic test for certain ovarian-related carcinomas. This certification supports patient selection for Merck’s KEYTRUDA (pembrolizumab) in accordance with approved EU usage.
- Agilent won EU certification for its PD-L1 IHC 22C3 pharmDx (SK006) companion diagnostic in certain ovarian-related carcinomas. * The label expansion supports patient selection for Merck’s KEYTRUDA (pembrolizumab) in line with approved EU use. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607230800BIZWIRE_USPR_____20260723_BW876055) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)